Uridine diphosphate glucose dehydrogenase lactylation modification site detection method and application thereof

Through the detection method of lactation modification site of uridine diphosphate glucose dehydrogenase, the lactation modification site of UGDH protein was determined, providing new ideas for the research on lactation modification of non-histones. The developed molecular tools are helpful Understanding the pathogenesis of metabolic diseases and tumors provides new therapeutic hope.

CN119023855APending Publication Date: 2024-11-26THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411368754.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art has few studies on lactation modifications of non-histones, especially uridine diphosphate glucose dehydrogenase (UGDH), a key metabolic enzyme, and lacks effective detection methods and corresponding applications.

Method used

Provide a method for detecting lactic acidification modification sites of uridine diphosphate glucose dehydrogenase, including protein enrichment, protein gel electrophoresis, trypsinase and liquid chromatography-mass spectrometry analysis, and determined the lactic acidization of UGDH protein. The modification sites are lysine residues at positions 6 and 399, and specific inhibitors, activators, antigenic peptides and antibodies have been developed.

Benefits of technology

Revealed the new regulatory mechanism of UGDH protein, enriched the understanding of the regulatory mechanism of metabolic enzymes, and provided new perspectives and clues for the study of metabolic reprogramming and disease pathogenesis. The developed molecular tools are helpful in the study of metabolic diseases and tumors. Pathogenesis and may become a new drug target or treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023855A_ABST
    Figure CN119023855A_ABST
Patent Text Reader

Abstract

The invention discloses a detection method of uridine diphosphate glucose dehydrogenase lactylation modification sites and application thereof, and belongs to the technical field of biomedicine. According to the present invention, the lactic acid modification sites of the UGDH protein are determined to be the 6th lysine residue and the 399th lysine residue through detection; the discovery not only enriches the understanding of a metabolic enzyme regulation mechanism, but also provides a new thought for researching lactylation modification of other non-histone proteins, and provides a new view angle and clue for understanding biological processes such as metabolic reprogramming, disease occurrence and development and the like. Besides, the invention further discloses application of UGDH protein lactylation modification, the UGDH protein lactylation modification can be applied to specific inhibitors or activators, antigen peptides, antibodies and corresponding detection reagents, and the molecular tools can provide powerful support for research on pathogenesis of metabolic diseases, tumors and other diseases, can be possibly used as new drug targets or treatment means, and can be used for preparing the UGDH protein lactylation modification drugs. And a new hope is brought to prevention and treatment of related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biomedical technology, and in particular to a method for detecting a lactic acid modification site of UDP-glucose dehydrogenase and an application thereof. Background Art

[0002] Lactylation refers to the binding of accumulated lactic acid to lysine residues on proteins during cell metabolism. As a newly discovered post-translational modification of proteins in recent years, lactylation is important because it may be involved in regulating protein stability, activity and interaction with other molecules. This modification plays a key role in cellular response to energy stress, metabolic reprogramming and signal transduction. Especially in the tumor microenvironment, while lactic acid is a metabolic waste, it has also been found to act as a signal molecule, affecting protein function through lactylation, thereby promoting tumor growth and metastasis. The current protein lactylation site detection can detect multiple histone lactylation sites, such as lactylation at H3K18 and H4K16 sites.

[0003] UDP-glucose dehydrogenase (UGDH) is a key enzyme in the uronic acid pathway. However, there are relatively few studies on the lactylation modification of non-histone proteins, especially the lactylation modification of key metabolic enzymes such as UDP-glucose dehydrogenase. Summary of the invention

[0004] In view of the above-mentioned problems, the present invention aims to provide a method for detecting the lactylation modification site of UDP-glucose dehydrogenase (UGDH) and its application, which provides a new perspective for in-depth understanding of the regulatory mechanism of metabolic enzymes.

[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows: In one aspect, the present invention provides a method for detecting a UDP-glucose dehydrogenase lactate modification site, comprising the following steps: S1: UGDH protein enrichment; S2: The extracted UGDH protein was subjected to protein gel electrophoresis and Coomassie brilliant blue staining in turn, and the corresponding band was cut according to the molecular weight of UGDH; S3: Detect and analyze the lactic acid sites on the rubber strip samples cut in step S2.

[0006] Furthermore, the specific operation of step S1 includes the following steps: S101: cells were lysed using cell lysis buffer containing 1% PMSF to extract total protein; S102: Add 20 μL of Protein A / G agarose beads to the extracted protein solution, incubate at 4°C for 1 hour, centrifuge the protein lysate and agarose beads to remove the precipitated agarose beads; S103: Add 20 μL of Protein A / G agarose beads and 4 μg of UGDH antibody to the protein solution pretreated in step S102, and incubate on a rotating rack at 4°C for 12 hours; S104: centrifugation to collect the precipitated agarose beads; S105: resuspend agarose beads with cell lysis buffer; S106: Add 40 μL of cell lysate and 10 μL of 5x loading buffer to the agarose beads precipitated at the bottom of the centrifuge tube, heat at 100°C, and then centrifuge again to remove the agarose beads and collect the liquid. The UGDH protein enrichment is completed.

[0007] Furthermore, the specific operation of step S3 includes the following steps: S301: Cutting rubber; S302: using pancreatic enzyme to enzymatically digest the gel block; S303: Liquid chromatography-mass spectrometry analysis; S304: Database search to determine the lactylation modification site.

[0008] Furthermore, in step S304, the lactylation modification sites of the UGDH protein are the 6th and 399th lysine residues.

[0009] On the other hand, the present invention also provides the use of UGDH protein modified by lactylation of lysine residues at positions 6 and 399 in specific inhibitors or activators.

[0010] On the other hand, the present invention also provides the use of UGDH protein with lactic acid modified lysine residues at positions 6 and 399 in antigenic peptides and antibodies with lactic acid modified lysine residues at positions 6 and 399 of human UGDH protein.

[0011] Furthermore, the antibody is prepared by immunizing animals using the lactated antigen peptides at lysine 6 and 399 of human UGDH protein as immune sources.

[0012] On the other hand, the present invention also provides the use of the aforementioned antigenic peptide and antibody in the preparation of a preparation for detecting lactylation at lysine 6 and 399 of human UGDH protein.

[0013] Furthermore, the preparation includes a kit and a probe.

[0014] The beneficial effects of the present invention are: 1. This invention reveals a new regulatory mechanism of UGDH protein - lactic acid modification, and through lactic acid site detection, it is determined that the lactic acid modification sites of UGDH protein are lysine residues 6 and 399. This discovery not only enriches the understanding of the regulatory mechanism of metabolic enzymes, but also provides new ideas for studying the lactic acid modification of other non-histone proteins. At the same time, it also provides new perspectives and clues for understanding biological processes such as metabolic reprogramming and disease occurrence and development.

[0015] 2. Based on the exploration of the lactic acid modification site of UGDH protein in the present invention, the present invention is also expected to develop specific inhibitors or activators, antigenic peptides, antibodies and corresponding detection reagents for lactic acid modification of UGDH protein. These molecular tools will provide strong support for our study of the pathogenesis of metabolic diseases, tumors and other diseases. In addition, they may also become new drug targets or treatment methods, bringing new hope for the prevention and treatment of related diseases. Therefore, the application prospects of the present invention are very broad. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a cropped image of the UGDH band in the present invention.

[0017] Figure 2 This is a flow chart of the lactylation site detection in the present invention.

[0018] Figure 3 This is the mass spectrum of the peptide segment with lactic acid modification at the 6th lysine (K6) site, which is unique to UGDH detected in the present invention.

[0019] Figure 4 This is the mass spectrum of the peptide segment with lactic acid modification at the 399th lysine (K399) site, which is unique to UGDH detected in the present invention.

[0020] Figure 5 The results of Alcian blue staining of human chondrocytes after lactic acid (lac) was used to promote lactic acid modification of the 6th and 399th lysine residues of UGDH in the present invention. DETAILED DESCRIPTION

[0021] In order to enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments. Example 1

[0022] Embodiment 1 provides a method for detecting a lactic acid modification site of uridine diphosphate glucose dehydrogenase (UGDH), comprising the following steps: 1. UGDH protein enrichment First, human articular chondrocytes were lysed using a cell lysis buffer (Beyotime, P0013) containing 1% PMSF (Beyotime, ST506) to extract at least 1 mg of total protein. 20 μL of Protein A / G agarose beads (Santa Cruz Biotechnology, sc-2003) were added to the extracted protein solution and incubated at 4°C for 1 hour. The protein lysate and agarose beads were centrifuged at 1000 g for 5 minutes to remove the precipitated agarose beads. This step is to remove proteins that non-specifically bind to the agarose beads.

[0023] Then, 20 μL of Protein A / G agarose beads and 4 μg of UGDH antibody (Sino Biological, 200912-T44) were added to the pretreated protein solution and incubated on a rotating rack at 4°C for 12 hours. After 12 hours, the solution was centrifuged at 1000 g for 5 minutes to collect the precipitated agarose beads. Then the agarose beads were resuspended with cell lysis buffer. The solution was centrifuged at 1000 g for 5 minutes again to collect the precipitated agarose beads. The centrifugation and resuspension steps were repeated three times. Finally, 40 μL of cell lysis buffer and 10 μL of 5x loading buffer (Beyotime, P0015) were added to the agarose beads precipitated at the bottom of the centrifuge tube, heated at 100°C for 10 minutes, and then centrifuged at 1000 g for 5 minutes to remove the agarose beads and collect the liquid. The enrichment of UGDH protein was completed.

[0024] 2. Perform protein gel electrophoresis on the extracted UGDH protein, followed by Coomassie Brilliant Blue staining. Cut the corresponding bands according to the molecular weight of UGDH, as shown in the attached Figure 1 shown.

[0025] 3. Perform detection and analysis of lactic acid sites on the rubber strip samples cut in step 2.

[0026] The detection and analysis process of lactylation sites is shown in the attached Figure 2 shown.

[0027] The materials and reagents required for lactation site detection are shown in Table 1 below.

[0028] Table 1 Materials and reagents required for lactylation site detection

[0029] 3.1 Cutting Rubber Use a surgical blade to cut the film into blocks of approximately 1 mm3 in size and divide them into clean EP tubes.

[0030] 3.2 Pancreatic enzymatic hydrolysis Wash the gel block 2-3 times, add 200μL of decolorizing solution (35% acetonitrile ACN and 50mM NH4HCO3), shake gently for decolorization, add 200μL of 70% ACN for dehydration, add 200μL of 25mM DTT (dithiothreitol), leave at room temperature for 1h, discard the supernatant; add 200μL of 50mM IAM (iodoacetamide), leave at room temperature in the dark for 10min, discard the supernatant; add 200μL of 70% ACN for dehydration; finally, add pancreatin at a mass ratio of 1:50 (pancreatin: protein), and digest at 37 °C overnight. Then add pancreatin at a mass ratio of 1:100 (pancreatin: protein) and continue digestion for 4h.

[0031] 3.3 Liquid chromatography-mass spectrometry analysis ① Dissolve each pre-separated component in the liquid phase, centrifuge at 20,000 g for 5 min, and transfer the supernatant to the loading bottle; ② Use LC-MS system to analyze each component for 1 h, with a sample load of approximately 2 µg.

[0032] Among them, the parameter settings of nanoliter ultra-high performance liquid chromatography in the liquid-mass spectrometry system are shown in Table 2 below, and the parameter settings of the quadrupole orbital trap mass spectrometry are shown in Table 3 below.

[0033] Table 2 Parameter settings of nano-ULPLC in LC / MS system

[0034] Table 3 Parameter settings of the quadrupole orbital trap mass spectrometer in the LC-MS system

[0035] 3.4 Database search to identify lactylation modification sites The secondary mass spectrometry data were searched using pFind (v3.1). Search parameter settings: Human proteome database, anti-library added to calculate the false positive rate (FDR) caused by random matching, and a common contamination library was added to the database to eliminate the impact of contaminating proteins in the identification results; the enzyme cleavage method was set to Trypsin / P; the number of missed cleavage sites was set to 2; the minimum length of the peptide was set to 7 amino acid residues; the maximum number of peptide modifications was set to 5; the primary parent ion mass error tolerance was set to 20 ppm, and the secondary fragment ion mass error tolerance was 20 ppm. Lysine lactylation modification was added as a variable modification. The FDR for protein identification and PSM identification was set to 1%. The database search results are shown in the attached Figure 3 and attached Figure 4 As shown, attached Figure 3The peptide sequence that has undergone lactic acid modification in the test sample is shown in the figure, and the lactic acid modification site is located at lysine K6 marked in red. This peptide is unique to the UGDH protein. Figure 4 The figure shows another peptide sequence that is lactylated in the sample tested, and the lactylated site is located at the red-marked lysine K399. This peptide is unique to the UGDH protein. The two mass spectra show that the lysine residues at positions 6 and 399 of the UGDH protein are lactylated. Example 2

[0036] According to the results obtained in Example 1, Example 2 provides the use of UGDH protein modified by lactylation of lysine residues at positions 6 and 399 in specific inhibitors or activators.

[0037] Specifically, UGDH is a dehydrogenase that catalyzes the conversion of UDP-glucose into UDP-glucuronic acid, which is a precursor of glycosaminoglycans (GAGs). Therefore, UGDH can regulate the synthesis of glycosaminoglycans. Figure 5 As shown in the figure, after lactic acid (lac) was used to promote the lactic acid modification of the 6th and 399th lysine residues of UGDH, the catalytic activity of UGDH protein decreased, the Alcian blue staining of human chondrocytes became lighter, and the synthesis of glycosaminoglycans decreased. Therefore, the lactic acid modification of the 6th and 399th lysine residues of UGDH can serve as an inhibitor of glycosaminoglycan synthesis.

[0038] In addition, the UGDH protein with lactic acid modified at the 6th and 399th lysine residues can also be used in the synthesis of lactic acid antigenic peptides of human UGDH protein at lysine 6th and 399th positions and antibodies with lactic acid modified at lysine 6th and 399th positions of human UGDH protein, wherein the antigenic peptide refers to the peptide sequence of UGDH with lactic acid modified at the 6th and 399th lysine residues, and the antibody is prepared by immunizing animals with the antigenic peptide as the immunogen.

[0039] The antigen peptides and antibodies of the present invention can be further used in the preparation of preparations for detecting lactylation of lysine 6 and 399 of human UGDH protein, and can also be used in the preparation of products (including kits, probes, etc.) for tumor diagnosis, efficacy assessment or prognosis assessment.

[0040] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. Detection method of lactic acid modification site of UDP-glucose dehydrogenase, It is characterized in that The following steps are involved: S1: UGDH protein enrichment; S2: The extracted UGDH protein was subjected to protein gel electrophoresis and Coomassie brilliant blue staining in sequence, and the corresponding band was cut according to the molecular weight of UGDH; S3: Detect and analyze the lactic acid sites on the rubber strip samples cut in step S2.

2. The detection method according to claim 1, Features: The specific operation of step S1 includes the following steps: S101: cells were lysed using cell lysis buffer containing 1% PMSF to extract total protein; S102: Add 20 μL of Protein A / G agarose beads to the extracted protein solution, incubate at 4°C for 1 hour, centrifuge the protein lysate and agarose beads to remove the precipitated agarose beads; S103: Add 20 μL of Protein A / G agarose beads and 4 μg of UGDH antibody to the protein solution pretreated in step S102, and incubate on a rotating rack at 4°C for 12 hours; S104: centrifugation to collect the precipitated agarose beads; S105: resuspend agarose beads with cell lysis buffer; S106: Add 40 μL of cell lysate and 10 μL of 5x loading buffer to the agarose beads precipitated at the bottom of the centrifuge tube, heat at 100°C, and then centrifuge again to remove the agarose beads and collect the liquid. The UGDH protein enrichment is completed.

3. The detection method according to claim 2, Features: The specific operation of step S3 includes the following steps: S301: Cutting rubber; S302: using pancreatin to enzymatically digest the gel block; S303: Liquid chromatography-mass spectrometry analysis; S304: Database search to determine the lactylation modification site.

4. The detection method according to claim 3, Features: In step S304, the lactylation modification sites of the UGDH protein are the 6th and 399th lysine residues.

5. Application of UGDH protein with lactylation modification of lysine residues at positions 6 and 399 as a specific inhibitor or activator.

6. Application of UGDH protein with lactylated lysine residues at positions 6 and 399 in antigenic peptides and antibodies with lactylated lysine residues at positions 6 and 399 of human UGDH protein.

7. The use according to claim 6, Features: The antibody is prepared by immunizing animals with the lactic acid antigen peptides at the 6th and 399th lysine of human UGDH protein as immune sources.

8. Use of the antigenic peptide and antibody as claimed in claim 6 in the preparation of a preparation for detecting lactylation of lysine 6 and 399 of human UGDH protein.

9. The use according to claim 8, Features: The preparation includes a kit and a probe.